关注
Wei Hong
Wei Hong
Medical oncologist, biostatistician, PhD candidate
在 mh.org.au 的电子邮件经过验证
标题
引用次数
引用次数
年份
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
J Tie, Y Wang, J Cohen, L Li, W Hong, M Christie, HL Wong, S Kosmider, ...
PLoS medicine 18 (5), e1003620, 2021
1172021
Post-operative stereotactic radiosurgery following excision of brain metastases: A systematic review and meta-analysis
ZZ Akanda, W Hong, S Nahavandi, N Haghighi, C Phillips, DL Kok
Radiotherapy and Oncology 142, 27-35, 2020
632020
Financial toxicity in patients with cancer attending a public Australian tertiary hospital: A pilot study
L McLean, W Hong, SA McLachlan
Asia‐Pacific Journal of Clinical Oncology 17 (3), 245-252, 2021
162021
Real-world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2-negative metastatic breast cancer
V Wong, R de Boer, S Baron-Hay, R Blum, F Boyle, S Chua, K Clarke, ...
Clinical Breast Cancer 22 (8), 792-800, 2022
72022
Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting
L Kostos, W Hong, B Lee, B Tran, SW Lok, A Anton, G Gard, YH To, ...
International Journal of Cancer 149 (2), 409-419, 2021
72021
Description of the effect of patient flow, junior doctor supervision and pandemic preparation on the ability of emergency physicians to provide direct patient care
A Lim, N Gupta, A Lim, W Hong, K Walker
Australian Health Review 44 (5), 741-747, 2020
62020
An exploration of testicular cancer survivors’ experience of ejaculatory dysfunction following retroperitoneal lymph node dissection—a sub-study of the PREPARE clinical trial
C Conduit, AD Hutchinson, M Leonard, S O.’Haire, M Moody, B Thomas, ...
Journal of Cancer Survivorship, 1-10, 2023
32023
CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906.
C Conduit, PS Grimison, JH Lewin, AR Hansen, JF Lynam, AJ Weickhardt, ...
Journal of Clinical Oncology 41 (16_suppl), TPS5100-TPS5100, 2023
32023
A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment …
C Conduit, W Hong, F Martin, B Thomas, N Lawrentschuk, J Goad, ...
Frontiers in Oncology 12, 931509, 2022
32022
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
L Gately, C Mesía, JM Sepúlveda, S Del Barco, E Pineda, R Gironés, ...
Journal of Neuro-Oncology 166 (3), 407-415, 2024
22024
Long-term control of melanoma adrenal metastasis treated with radiotherapy
B McCann, M Higgins, DL Kok, W Hong, R Alipour, MST Chua
Melanoma Research 32 (3), 166-172, 2022
22022
Improving clinical trials using Bayesian adaptive designs: a breast cancer example
W Hong, SA McLachlan, M Moore, RK Mahar
BMC Medical Research Methodology 22 (1), 133, 2022
22022
Biology and clinical implications of fecal occult blood test screen-detected colorectal cancer
S Mendis, W Hong, S Ananda, I Faragher, I Jones, M Croxford, M Steel, ...
JNCI Cancer Spectrum 6 (1), pkab100, 2022
22022
Personalizing first-line systemic therapy in metastatic colorectal cancer: is there a role for initial low-intensity therapy in 2021 and beyond? A perspective from members of …
C Dunn, W Hong, P Gibbs, S Ackland, K Sjoquist, NC Tebbutt, T Price, ...
Clinical colorectal cancer 20 (3), 245-255, 2021
22021
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
V Wong, M Lee, R Wong, J Tie, J Shapiro, J Desai, L Nott, S Steel, ...
Targeted Oncology 16, 227-236, 2021
22021
Trial in progress: PREPARE—Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of …
C Conduit, JH Lewin, IW Sim, HM Dhillon, W Hong, A Hutchinson, ...
Journal of Clinical Oncology 41 (6_suppl), TPS432-TPS432, 2023
12023
Circulating Tumor DNA (ctDNA) as a marker of residual disease and recurrence risk in resected stage I IV epithelial ovarian cancer (EOC).
S Ananda
12023
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer
CY Chong, A Jalali, HL Wong, M Loft, R Wong, M Lee, L Gately, W Hong, ...
Asia‐Pacific Journal of Clinical Oncology 18 (5), e363-e368, 2022
12022
P-187 Epidermal growth factor receptor inhibitors (EGFRi) in patients with left-side, RAS wildtype metastatic colorectal cancer: Clinician use and outcomes for patients
J McKenzie, S Kosmider, R Wong, Y To, J Shapiro, C Dunn, M Burge, ...
Annals of Oncology 33, S316, 2022
12022
Impact of adjuvant chemotherapy and patient age on patterns of metastatic recurrence in stage III colorectal cancer.
G Gard, YH To, L Gately, M Croxford, I Jones, I Faragher, M Steel, W Hong, ...
Journal of Clinical Oncology 39 (3_suppl), 122-122, 2021
12021
系统目前无法执行此操作,请稍后再试。
文章 1–20